Iris M van Hagen1, Eric Boersma2, Mark R Johnson3, Sara A Thorne4, William A Parsonage5, Pilar Escribano Subías6, Agata Leśniak-Sobelga7, Olga Irtyuga8, Khaled A Sorour9, Nasser Taha10, Aldo P Maggioni11,12, Roger Hall13, Jolien W Roos-Hesselink1,12. 1. Department of Cardiology, Erasmus MC, Thoraxcenter, Department of Cardiology Ba583a, PO Box 2040, 3000, CA, Rotterdam, the Netherlands. 2. Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands. 3. Department of Obstetrics, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK. 4. Adult Congenital Heart Disease Unit, Department of Cardiology, Queen Elizabeth Hospital, Birmingham, UK. 5. Department of Cardiology, Royal Brisbane and Women's Hospital, Brisbane, Australia. 6. Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain. 7. Department of Cardiac and Vascular Diseases, Jagiellonian University School of Medicine, John Paul II Hospital, Kraków, Poland. 8. Almazov Federal North-West Medical Research Centre, Saint Petersburg, Russia. 9. Department of Cardiology, Kasr El Aini Hospital, Faculty of Medicine, Cairo University, Egypt. 10. Department of Cardiology, Faculty of Medicine, El Minya University Hospital, Minya, Egypt. 11. ANMCO Research Centre, Florence, Italy. 12. ESC, Sophia Antipolis Cedex, France. 13. Department of Cardiology, Norwich Medical School, University of East Anglia, Norwich, UK.
Abstract
AIMS: To validate the modified World Health Organization (mWHO) risk classification in advanced and emerging countries, and to identify additional risk factors for cardiac events during pregnancy. METHODS AND RESULTS: The ongoing prospective worldwide Registry Of Pregnancy And Cardiac disease (ROPAC) included 2742 pregnant women (mean age ± standard deviation, 29.2 ± 5.5 years) with established cardiac disease: 1827 from advanced countries and 915 from emerging countries. In patients from advanced countries, congenital heart disease was the most prevalent diagnosis (70%) while in emerging countries valvular heart disease was more common (55%). A cardiac event occurred in 566 patients (20.6%) during pregnancy: 234 (12.8%) in advanced countries and 332 (36.3%) in emerging countries. The mWHO classification had a moderate performance to discriminate between women with and without cardiac events (c-statistic 0.711 and 95% confidence interval (CI) 0.686-0.735). However, its performance in advanced countries (0.726) was better than in emerging countries (0.633). The best performance was found in patients with acquired heart disease from developed countries (0.712). Pre-pregnancy signs of heart failure and, in advanced countries, atrial fibrillation and no previous cardiac intervention added prognostic value to the mWHO classification, with a c-statistic of 0.751 (95% CI 0.715-0.786) in advanced countries and of 0.724 (95% CI 0.691-0.758) in emerging countries. CONCLUSION: The mWHO risk classification is a useful tool for predicting cardiac events during pregnancy in women with established cardiac disease in advanced countries, but seems less effective in emerging countries. Data on pre-pregnancy cardiac condition including signs of heart failure and atrial fibrillation, may help to improve preconception counselling in advanced and emerging countries.
AIMS: To validate the modified World Health Organization (mWHO) risk classification in advanced and emerging countries, and to identify additional risk factors for cardiac events during pregnancy. METHODS AND RESULTS: The ongoing prospective worldwide Registry Of Pregnancy And Cardiac disease (ROPAC) included 2742 pregnant women (mean age ± standard deviation, 29.2 ± 5.5 years) with established cardiac disease: 1827 from advanced countries and 915 from emerging countries. In patients from advanced countries, congenital heart disease was the most prevalent diagnosis (70%) while in emerging countries valvular heart disease was more common (55%). A cardiac event occurred in 566 patients (20.6%) during pregnancy: 234 (12.8%) in advanced countries and 332 (36.3%) in emerging countries. The mWHO classification had a moderate performance to discriminate between women with and without cardiac events (c-statistic 0.711 and 95% confidence interval (CI) 0.686-0.735). However, its performance in advanced countries (0.726) was better than in emerging countries (0.633). The best performance was found in patients with acquired heart disease from developed countries (0.712). Pre-pregnancy signs of heart failure and, in advanced countries, atrial fibrillation and no previous cardiac intervention added prognostic value to the mWHO classification, with a c-statistic of 0.751 (95% CI 0.715-0.786) in advanced countries and of 0.724 (95% CI 0.691-0.758) in emerging countries. CONCLUSION: The mWHO risk classification is a useful tool for predicting cardiac events during pregnancy in women with established cardiac disease in advanced countries, but seems less effective in emerging countries. Data on pre-pregnancy cardiac condition including signs of heart failure and atrial fibrillation, may help to improve preconception counselling in advanced and emerging countries.
Authors: Betül Toprak; Katharina Govorov; Katinka Kurz; Dora Csengeri; Jessica Weimann; Dennis Witte; Kurt Hecher; Bettina Hollwitz; Anne Hansen; Carsten Rickers; Christina Magnussen; Yskert von Kodolitsch; Tanja Zeller; Stefan Blankenberg; Christoph Sinning; Paulus Kirchhof; Elvin Zengin-Sahm Journal: Cardiovasc Diagn Ther Date: 2021-12
Authors: Nidaa Mikail; Alexia Rossi; Susan Bengs; Ahmed Haider; Barbara E Stähli; Angela Portmann; Alessio Imperiale; Valerie Treyer; Alexander Meisel; Aju P Pazhenkottil; Michael Messerli; Vera Regitz-Zagrosek; Philipp A Kaufmann; Ronny R Buechel; Cathérine Gebhard Journal: Eur J Nucl Med Mol Imaging Date: 2022-08-17 Impact factor: 10.057
Authors: Shannon L Son; Lauren L Hosek; Miranda C Stein; Amanda A Allshouse; Anna B Catino; Arvind K Hoskoppal; Daniel A Cox; Kevin J Whitehead; Ian M Lindsay; Sean Esplin; Torri D Metz Journal: Am J Obstet Gynecol Date: 2021-07-28 Impact factor: 8.661